Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 14/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582072 | 1.00 | PLG (0.65) | PLGGABRA1GABRG2GABRB3MGLL | |
| SCHEMBL582071 | 1.00 | PLG (0.65) | PLGGABRA1GABRG2GABRB3MGLL | |
| SCHEMBL582073 | 1.00 | PLG (0.65) | PLGGABRA1GABRG2GABRB3MGLL | |
| Acetic Acid SCHEMBL27852917 | 0.93 | PLG (0.58) | PLGGABRA1GABRG2GABRB3 | |
| Acetic Acid SCHEMBL27869781 | 0.93 | PLG (0.58) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581970 | 0.88 | PLG (0.56) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL582077 | 0.88 | PLG (0.56) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581971 | 0.88 | PLG (0.56) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581969 | 0.88 | PLG (0.56) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL582286 | 0.87 | PLG (0.59) | PLGGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180338964-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | EMERITI PHARMA AB (SE) | 2018-11-29 | — | — | US | claimed |
| US-20170360766-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | EMERITI PHARMA AB (SE) | 2017-12-21 | — | — | US | claimed |
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | claimed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | claimed |
| US-20180338964-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | EMERITI PHARMA AB (SE) | 2018-11-29 | — | — | US | disclosed |
| US-20170360766-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | EMERITI PHARMA AB (SE) | 2017-12-21 | — | — | US | disclosed |
| EP-3233189-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(2H)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | Emeriti Pharma AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016099397-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(2H)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | EMERITI PHARMA AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338964-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | DPM1, SUCLG1, POLR1C | PLG 1684/4885GABRA1 765/4885GABRG2 752/4885 |
| US-20170360766-A1 | 3-(PIPERIDIN-4-YL)-ISOXAZOL-3(OH)-ONES FOR TREATMENT OF DERMATOLOGIC DISORDERS | DPM1, SUCLG1, POLR1C | PLG 1684/4885GABRA1 765/4885GABRG2 752/4885 |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | PLG 4861/4885GABRA1 237/4885GABRG2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.